JPRN-jRCT2080222338未知3 期
A Phase 3, open-label study of LX-P in patients with various pains.
EAD CHEMICAL COMPANY, LIMITED0 个研究点目标入组 264 人开始时间: 2013年12月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with well-defined as each target disease and judged as suitable for topical NSAIDs treatment, etc.
排除标准
- •Patients with symptoms/findings falling under the contraindications or relative contraindications described in the package insert for loxoprofen sodium hydrate tape, etc.
研究者
相似试验
未知
3 期
Phase III clinical trial of L-105 in patients with hepatic encephalopathyH.E.JPRN-jRCT2080222041ASKA Pharmaceutical Co., Ltd.180
已完成
3 期
Phase III pediatric study with the L-PZQ ODTsPACTR201810634034543Merck KGaA311
进行中（未招募）
1 期
Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancerEUCTR2016-003315-35-GBPfizer Inc., 235 East 42nd Street, New York, NY 10017280
进行中（未招募）
1 期
Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancerAdvanced ALK positive non small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003315-35-DKPfizer Inc., 235 East 42nd Street, New York, NY 10017280
进行中（未招募）
1 期
Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancerEUCTR2016-003315-35-NLPfizer Inc, 235 East 42nd Street, New York, NY 10017280